Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alabama bill targets andro, DHEA

This article was originally published in The Tan Sheet

Executive Summary

The sale of dietary supplements containing androstanedione, dehydroepiandrosterone or ephedrine alkaloids to consumers under 18 years of age would be prohibited under a bill recently introduced in the Alabama state legislature. The proposal requires that sellers obtain valid identification from purchasers, and makes violation of the law a Class A misdemeanor. HB 356, sponsored by Rep. Tommy Sherer (D) and House Majority leader Ken Guin (D), was referred to the Health Committee March 15. In other DHEA-related legislative activity, an Oregon state bill would bar school employees from endorsing use of performance-enhancing supplements by students, while a federal bill by Sen. Charles Grassley, R-Iowa, would list DHEA as an anabolic steroid under the Controlled Substances Act (1"The Tan Sheet" March 19, 2007, In Brief and 2"The Tan Sheet" March 12, 2007, In Brief)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel